Bupropion (Wellbutrin) Should Be Avoided in Patients with Hemiplegic Migraine
Bupropion is contraindicated in patients with a history of hemiplegic migraine due to the significantly elevated seizure risk in this population. The FDA drug label explicitly states that bupropion is contraindicated in patients with seizure disorders or conditions that increase seizure risk 1, and hemiplegic migraine falls into this high-risk category.
Why This Matters: The Seizure Connection
Bupropion's Seizure Risk
Bupropion lowers the seizure threshold in a dose-dependent manner. The FDA label documents seizure incidence of approximately 0.1% at standard doses (up to 300 mg/day) and 0.4% at higher doses (300-450 mg/day), with risk increasing nearly tenfold at doses between 450-600 mg/day 1. Even at therapeutic doses and blood levels, seizures can occur in patients without any predisposing factors 2.
Hemiplegic Migraine as a Seizure Risk Factor
Hemiplegic migraine is specifically identified as an "uncommon migraine condition" requiring special consideration for preventive therapy 3. More critically, epilepsy co-occurs in approximately 40% of patients with familial hemiplegic migraine (78 of 195 individuals in a systematic review) 4. The genetic mutations causing hemiplegic migraine (CACNA1A, ATP1A2, SCN1A, PRRT2) affect ion channels that also predispose to seizures 4.
The American Heart Association guidelines specifically recommend avoiding certain medications in children with hemiplegic migraine due to vascular and neurological risks 5, reflecting the heightened vulnerability of this patient population.
Clinical Decision-Making Algorithm
Step 1: Identify the diagnosis
- Does the patient have hemiplegic migraine (with motor weakness during attacks)?
- If yes → Do not prescribe bupropion
Step 2: Consider safer alternatives for depression/smoking cessation
- For depression in migraine patients: Consider SSRIs (sertraline, fluoxetine) or tricyclic antidepressants (amitriptyline), which are actually first-line preventive agents for migraine 3
- For smoking cessation: Use varenicline, combination NRT, or NRT alone 6
Step 3: If bupropion is already prescribed
- Discontinue immediately upon learning of hemiplegic migraine history
- Monitor for withdrawal symptoms
- Transition to alternative therapy
Important Caveats
The Seizure Risk is Real, Not Theoretical
Multiple case reports document new-onset seizures in patients without prior seizure history who were prescribed bupropion 7, 2. One case involved a 66-year-old woman with no seizure risk factors who developed seizures just 4 days after starting bupropion 7. The risk persists even at modest blood levels (83 ng/ml) and standard doses 2.
Additional Risk Factors to Consider
The FDA label identifies multiple conditions that further increase seizure risk when combined with bupropion 1:
- Concomitant medications lowering seizure threshold (antipsychotics, tricyclic antidepressants, theophylline, corticosteroids)
- Metabolic disorders (hypoglycemia, hyponatremia, severe hepatic impairment)
- Abrupt discontinuation of alcohol, benzodiazepines, or barbiturates
- CNS tumors, severe stroke, or arteriovenous malformations
NCCN Guidelines Confirm the Contraindication
The National Comprehensive Cancer Network explicitly states: "Bupropion is contraindicated for patients with seizure risks (ie, stroke, brain metastases)" 6. While this guideline addresses oncology patients, the principle applies universally—bupropion should be avoided in any condition that increases seizure susceptibility.
Recommended Migraine Preventive Therapy Instead
For patients with hemiplegic migraine requiring preventive therapy, first-line agents include 3:
- Propranolol (80-240 mg/day)
- Amitriptyline (30-150 mg/day) - dual benefit for depression and migraine
- Divalproex sodium (500-1500 mg/day)
- Sodium valproate (800-1500 mg/day)
These medications have proven efficacy for migraine prevention and do not carry the seizure risk associated with bupropion.
Bottom Line for Clinical Practice
The combination of bupropion's inherent seizure risk and the elevated baseline seizure susceptibility in hemiplegic migraine creates an unacceptable risk-benefit ratio. This is not a relative contraindication requiring careful monitoring—it is an absolute contraindication based on FDA labeling and the underlying pathophysiology. Alternative treatments with better safety profiles are readily available for both depression and smoking cessation in this population.